Posted by Michael Wonder on 30 Dec 2021
PBS listing for Braftovi and cetuximab for metastatic bowel cancer patients with BRAFV600 mutation
30 December 2021 - Pierre Fabre Australia today announced that Braftovi (encorafenib) in combination with cetuximab will be listed on the PBS from 1 January 2022 for the treatment of metastatic bowel cancer patients with a BRAFV600 mutation following failure to respond to at least one prior systemic therapy.
This PBS listing is based on results from the BEACON CRC trial, the only Phase 3 trial to date to specifically study patients with previously treated metastatic bowel cancer with a BRAF V600 mutation.
